We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3,866.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDPH
RNS Number : 6005L
Dechra Pharmaceuticals PLC
13 September 2021
13 September 2021
Dechra Pharmaceuticals PLC
(the Company or Dechra)
Notification of Transactions by Person Discharging Managerial Responsibilities
On 10 September 2021, Dechra Pharmaceuticals PLC was notified by a Director of the Company and Person Discharging Managerial Responsibilities that he had completed the sale of part of his beneficial interest in Dechra.
Tony Griffin, Executive Director, has sold 17,500 ordinary shares in the Company to satisfy long term personal financial planning considerations and widen his investment portfolio. Following this transaction, Tony Griffin will continue to retain a beneficial holding of 28,150 ordinary shares which represents 0.026% of the current issued share capital in the Company.
The Notification of Dealing Form set out below is provided in accordance with the UK Market Abuse Regulation.
Notification of Dealing Form:
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") a) Name Tony Griffin ------------------------------------ ---------------------------------- 2. Reason for the notification ------------------------------------------------------------------------ a) Position/status Director ------------------------------------ ---------------------------------- b) Initial notification/amendment Initial Notification ------------------------------------ ---------------------------------- 3. Details of the Issuer ------------------------------------------------------------------------ a) Name Dechra Pharmaceuticals PLC ------------------------------------ ---------------------------------- b) LEI code 213800J4UVB5OWG8VX82 ------------------------------------ ---------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------ a) Description of the financial Ordinary Shares of 1 pence each instrument ISIN: GB0009633180 Identification code ------------------------------------ ---------------------------------- b) Nature of the transaction Sale of Shares ------------------------------------ ---------------------------------- c) Price(s) and volumes(s) Price(s) Volume(s) GBP50.01492 17,500 ------------------------------------ ------------------- ------------- d) Aggregated information * Aggregate volume 17,500 GBP50.01492 GBP875,261.10 * Price * Total ------------------------------------ ---------------------------------- e) Date of the transaction 10 September 2021 ------------------------------------ ---------------------------------- f) Place of the transaction London Stock Exchange ------------------------------------ ---------------------------------- Enquiries: Dechra Pharmaceuticals PLC Ian Page, Chief Executive Office: +44 (0) 1606 814 730 Officer Paul Sandland, Chief Financial Office: +44 (0) 1606 814 730 Officer e-mail: corporate.enquiries@dechra.com TooleyStreet Communications Ltd Fiona Tooley, Director Office: +44 (0) 121 309 0099 e-mail: fiona@tooleystreet.com Mobile: +44 (0) 7785 703 523 ---------------------------------------- ------------------------------
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBDGDCBUBDGBX
(END) Dow Jones Newswires
September 13, 2021 08:53 ET (12:53 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions